Comparing seizure treatments in glioma patients
Official title: Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure
Run by Leiden University Medical Center · NCT03048084 · Data updated 2026-11-12
This study is testing which of two common seizure medications, levetiracetam or valproic acid, works better for people with glioma who have just had their first seizure.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Leiden University Medical Center Academic / other |
| Locations | 5 sites (Amsterdam and 4 other locations) |
| Status | Recruiting |
| Started | February 1, 2018 |
| Main results expected | January 1, 2028 |
| Study ends | July 1, 2029 |
| Registry record updated | August 26, 2026 |
| Trial ID | NCT03048084 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a histologically confirmed glioma who have experienced their first seizure within the last two weeks.
✕Probably not a fit
Patients who have previously been treated with anti-epileptic drugs or have a history of non-brain tumor related epilepsy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to compare the effectiveness of two commonly used anti-epileptic drugs, levetiracetam and valproic acid, in patients with glioma who have experienced their first seizure. The study is designed as a randomized controlled trial, where participants will be assigned to receive one of the two medications to determine which is more effective in reducing seizure frequency. Both drugs have similar toxicity profiles and do not interfere with chemotherapy, making them suitable for glioma patients. The trial seeks to provide evidence-based guidance for the treatment of seizures in this patient population.
Why it matters
Potential benefit: If successful, this study could provide clear recommendations for the most effective seizure treatment in glioma patients, improving their quality of life.
How similar studies have gone: While there is limited evidence directly comparing these two medications in glioma patients, similar studies in other populations have shown varying degrees of success with anti-epileptic drug comparisons.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically proven or suspected diffuse astrocytoma (Isocytrate Dehydrogenase-1 (IDH-1) wildtype or IDH-1 mutated), diffuse oligodendroglioma (IDH-1 mutated and 1p/19q co-deleted), anaplastic astrocytoma (IDH-1 wildtype or IDH-1 mutated), anaplastic oligodendroglioma (IDH-1 mutated and 1p/19q co-deleted), glioblastoma (IDH-1 wild-type or IDH-1 mutated), or diffuse astrocytoma not otherwise specified (NOS), anaplastic astrocytoma NOS, oligodendroglioma NOS, oligoastrocytoma NOS, anaplastic oligoastrocytoma NOS, anaplastic oligodendroglioma NOS or glioblastoma NOS. * Adult patients: ≥18 years of age * First epileptic seizure, no longer than 2 weeks ago * Monotherapy with antiepileptic drugs is considered most appropriate at the time of randomization * Willing to provide written informed consent Exclusion Criteria: * Previously treated with antiepileptic drugs, except emergency treatment in the past 2 weeks * History of non-brain tumor related epilepsy * Pregnancy * Presence of contra-indications for use of levetiracetam or valproic acid
Where it's running
-
Medisch Spectrum Twente
Enschede, Netherlands Recruiting -
Leiden University Medical Center
Leiden, Netherlands Recruiting -
Erasmus Medical Center
Rotterdam, Netherlands Recruiting -
Haaglanden Medical Center
The Hague, Netherlands Recruiting -
Amsterdam UMC
Amsterdam, Netherlands Suspended
Study contacts
- Study coordinator: Johan AF Koekkoek, MD, PhD
- Email: j.a.f.koekkoek@lumc.nl
- Phone: 0031715269111
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.